DUBLIN–(BUSINESS WIRE)–The “Inflammatory Pain – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “Inflammatory Pain – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Inflammatory Pain pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Inflammatory Pain R&D. The therapies under development are focused on novel approaches to treat/improve Inflammatory Pain.
Inflammatory Pain Emerging Drugs Chapters
This segment of the Inflammatory Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Inflammatory Pain Emerging Drugs
CNTX 6970: Centrexion Therapeutics
Centrexion’s lead drug candidate, CNTX 6970 is an orally administered small molecule in development for the treatment of inflammatory pain. The drug is a CCR 2 receptor antagonist with dual effects. It inhibits the immune cells from releasing potent cytokine CCL2 and further stop it from stimulating pain fibers and from sending signals for pain.
Inflammatory Pain: Therapeutic Assessment
This segment of the report provides insights about the different Inflammatory Pain drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Inflammatory Pain
There are approx. 3+ key companies which are developing the therapies for Inflammatory Pain. The companies which have their Inflammatory Pain drug candidates in the most advanced stage, i.e. phase II include, Centrexion Therapeutics.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as:
- Oral
- Subcutaneous
- Topical
- Intravenous
- Molecule Type
Products have been categorized under various Molecule types such as:
- Monoclonal Antibody
- Peptides
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Inflammatory Pain: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Inflammatory Pain therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Inflammatory Pain drugs.
Inflammatory Pain Report Insights
- Inflammatory Pain Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Inflammatory Pain Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
- How many companies are developing Inflammatory Pain drugs?
- How many Inflammatory Pain drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Inflammatory Pain?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Inflammatory Pain therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Inflammatory Pain and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Centrexion Therapeutics
Key Products
- CNTX 6970
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/7dl9oy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900